High-Grade Momentum Builds as Tesla Drilling Further Defines Robust Mineralization
Thickened Central Tesla Zone Expanded Further by New Results
Intercepts Demonstrate a Central Zone of Increased Mineralization per Vertical Metre
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Canadian Nuclear Laboratories and the University of Ottawa Accelerate Low Dose Radiation Research and Foster Next Generation of Scientists
CHALK RIVER, Ontario, June 09, 2025 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, and the University of Ottawa (uOttawa), one of Canada's most innovative universities, are pleased to announce a new partnership to advance knowledge, education, research and innovation in low dose radiation (LDR) exposure health effects. Leveraging the leading research organizations' complementary capabilities, the new partnership builds on CNL's global leadership in LDR research with the establishment of a CNL-led LDR innovation hub, accelerating research critical to public safety and the health of Canadians. It will also serve to increase capabilities, education and training opportunities to graduate students and early career researchers. The partnership will also extend uOttawa researchers' access to Atomic Energy of Canada Limited's world class facilities at Chalk River Laboratories, including the unique Biological Research Facility, associated irradiation facilities and LDR Tissue Bank, and establishes a CNL satellite laboratory within uOttawa's new Advanced Medical Research Centre (AMRC) – set to open in 2026. This physical presence will be co-located with the Ottawa Institute of Systems Biology (OISB) as well as uOttawa state-of-the-art Core Facilities, which altogether will support new research directions in radiation sciences and advanced organoid-based systems biology. These areas are rapidly developing strengths at uOttawa, positioning the university as a national, and potentially international, leader in this field. uOttawa will also offer reciprocal access to key research facilities on campus, in addition to those located at the faculty of medicine and in AMRC. 'As a major player in the global research and development effort to support LDR research, CNL is focused on the prevention or reduction of radiation exposure effects in workers, patients and the larger population,' says Dr. Stephen Bushby, Vice-President, Science & Technology, CNL. 'We are very excited to include uOttawa as a major partner in the work needed to shed light on this complex field of research.' As part of this partnership, CNL will be contributing towards the acquisition of a mass spectrometer, which will be installed in the in the Metabolomics Core Facility at uOttawa. This strategic investment, supporting collaborative initiatives between OISB and CNL, will enable leading-edge single-cell metabolomics and spatial metabolomics, a rapidly advancing field with transformative potential in biomedical research. This will be the only equipment of its kind in eastern Canada, offering unique capabilities for high-resolution chemical imaging at the cellular level. The instrument will not only serve researchers at uOttawa, but also attract national and international collaborators, firmly establishing uOttawa as a leader in metabolomics and precision health research. The mass spectrometer will be a central component of the new Spatial Biology and Single-Cell Suite (3S) within the AMRC. This cutting-edge suite will integrate transformative new technologies into a coordinated workflow that complements and enhances five existing and intensively used Core Facilities: Flow Cytometry, Metabolomics, Gene Editing, Cellular Imaging, and Bioinformatics. By bridging these platforms, 3S will significantly expand research capabilities in some of uOttawa's strongest areas of discovery, particularly brain, heart, and cancer biology—driving breakthroughs in systems biology, precision medicine, and therapeutic development. 'This new equipment, the only one of its kind in Eastern Canada, positions the University of Ottawa as a leader in metabolomics and precision health research, while attracting national and international collaborations,' says Julie St-Pierre, Interim Vice-President, Research and Innovation, uOttawa. This new partnership builds on over a decade of collaborative research involving CNL and multiple uOttawa faculties, including Engineering, Science and Medicine. These collaborations have advanced understanding of the biomedical impacts of LDR, including studies on DNA damage and repair, protein synthesis, epigenetics, mitochondrial biology, metabolism, immunity, and stem cell functions. As part of this partnership, CNL has also provided funding support for postdoctoral fellow stipends, further enabling high-impact research and talent development. With the field of LDR research growing and Canadian leadership in LDR research well-recognized, both organizations will continue to explore additional opportunities to further strengthen this partnership. About CNL As Canada's premier nuclear science and technology laboratory and working under the direction of Atomic Energy of Canada Limited (AECL), CNL is a world leader in the development of innovative nuclear science and technology products and services. Guided by an ambitious corporate strategy known as Vision 2030, CNL fulfills three strategic priorities of national importance – restoring and protecting the environment, advancing clean energy technologies, and contributing to the health of Canadians. By leveraging the assets owned by AECL, CNL also serves as the nexus between government, the nuclear industry, the broader private sector and the academic community. CNL works in collaboration with these sectors to advance innovative Canadian products and services towards real-world use, including carbon-free energy, cancer treatments and other therapies, non-proliferation technologies and waste management solutions. To learn more about CNL, please visit The University of Ottawa is powered by research. Located in Canada's capital, we bring together energetic and creative scholars to tackle urgent global challenges and to respond to emerging opportunities. As one of Canada's most innovative universities, we generate breakthroughs and discoveries that make a real difference in communities across Ontario, Canada and the world. Our thought leaders provide evidence-based insights that inform policy and support industry. Our influence keeps growing due to our vast range of international partnerships, including our membership in the U7+ Alliance. As the world's largest French-English university, we are a driving force in the Francophonie. To learn more about uOttawa, please visit uOttawa contact: media@ A photo accompanying this announcement is available at
Globe and Mail
an hour ago
- Globe and Mail
IonQ Pops on Nvidia Collab. How Should You Play the Quantum Computing Stock Here?
IonQ (IONQ) shares are inching up at writing after the quantum technology specialist announced successful results from a high-profile research collaboration with Nvidia (NVDA), Amazon (AMZN) and AstraZeneca (AZN). On Monday, the group demonstrated quantum-accelerated computational chemistry workflow that could dramatically reduce the time required for drug development. Including today's gain, IONQ stock is up 120% versus its year-to-date low in March. Significance of Nvidia Collaboration for IonQ Stock The aforementioned collaboration is meaningful for IonQ shares as it validates the company's hybrid quantum-classical computing model in a real-world, high-stakes application: drug discovery. By linking its quantum hardware with Nvidia's advanced GPU acceleration and AWS' scalable infrastructure, the NYSE-listed firm has demonstrated tangible value in a notoriously computation-heavy sector. Not only do the findings strengthen IonQ's commercial credibility, but they also position it as a key player in the fast-emerging market of quantum-enhanced molecular modeling. Simply put, the research could open doors for more enterprise partnerships and significant revenue opportunities, which may translate to an increase in this quantum computing stock's price over time. IONQ Shares Gain on Oxford Ionics Acquisition IonQ shares are trending up at the time of writing also because the NYSE-listed firm announced a $1.1 billion acquisition of Oxford Ionics on Monday. Bringing the UK-based startup, known for its innovative trapped-ion quantum computing systems, under its umbrella strengthens IONQ's technology portfolio and global presence. The deal could accelerate IonQ's roadmap by integrating Oxford's breakthroughs with its hardware and cloud infrastructure. It also positions the company as a more formidable player in the race for commercial quantum advantage, expanding its tale base and IP. Still, analysts recommend caution in buying IONQ stock at current levels. Is It Too Late to Invest in IonQ? According to Wall Street analysts, a massive rally in IonQ shares over the past three months has baked in a lot of the good news already. While the consensus rating on IONQ still currently sits at ' Moderate Buy,' the mean target of $40 suggests the quantum computing stock is fairly valued and lacks any further upside from here.
CTV News
3 hours ago
- CTV News
Canadian safety institute announces research projects as global focus shifts to AI adoption
Innovation, Science and Industry Minister Francois-Philippe Champagne, right, and founder and scientific director of MILA-Quebec Artificial Intelligence Institute Yoshua Bengio answer media questions following the launch the Canadian Artificial Intelligence Safety Institute in Montreal on Tuesday, Nov. 12, 2024. THE CANADIAN PRESS/Christinne Muschi OTTAWA — The Canadian Artificial Intelligence Safety Institute will fund research projects focusing on misinformation, generative AI and the safety of autonomous systems. It says the initial 10 projects will receive $100,000 each from its research program. They include an initiative led by AI pioneer Yoshua Bengio that will look at the hidden reasons driving decisions by large language models, a type of generative AI focused on text. The Canadian AI Safety Institute was launched last year, part of a global network of publicly backed safety institutes that emerged following a wave of calls from experts for AI regulation. But there has been a global shift towards focusing on AI adoption over safety initiatives in recent months. In Canada, the Liberal government plans to prioritize AI's economic potential as it hosts the upcoming G7 summit, and new AI minister Evan Solomon has said nothing so far about his job description. Article by Anja Karadeglija.
